Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company...
immunotherapy
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy...
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage...
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural...
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate,...
High Throughput Screening Market to Reach USD 17,880 Million by 2031, Driven by Drug Discovery Advancements | Valuates Reports
BANGALORE, India, March 26, 2026 /PRNewswire/ -- What is the Market Size of High Throughput Screening?The global High Throughput Screening...
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via...
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via...
Preliminary results for the year ended 31 December 2025
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end...
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026...
Tivic Reports Full Year 2025 Results
Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding PartnershipsConference Call to be...
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV;...
BeyondSpring Reports 2025 Year-End Financial Results
Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs....
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously...
First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile – Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases
NEW YORK, March 24, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral...
OncoHost Wins 2026 Artificial Intelligence Excellence Award in Health Category
Recognition honors organizations delivering measurable impact through artificial intelligenceBINYAMINA, Israel and CARY, N.C., March 24, 2026 /PRNewswire/ -- OncoHost, an...
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab demonstrates synergy with standard-of-care therapies, supports...
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq...
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3...